ArticleJournal of virology1998
Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin alpha.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 56 citations in OpenAlex.
- Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.Cancer gene therapy · 2003Trial
- Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.Cancer gene therapy · 2003Trial
- Article
- Innate immunity to adenovirus: lessons from mice.FEBS letters · 2019Review
- Article
- Th17 cells and mucosal host defense.Seminars in immunology · 2007Review
- A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients.Cancer gene therapy · 2007Article
- Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.Gene therapy · 2007Article
- Oncolytic viral therapies.Cancer gene therapy · 2004Review
- An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint.Gene therapy · 2004Article
- Dissection of antiviral and immune regulatory functions of tumor necrosis factor receptors in a chronic lymphocytic choriomeningitis virus infection.Journal of virology · 2004Article
- Cell targeting in anti-cancer gene therapy.The Malaysian journal of medical sciences : MJMS · 2004Article
- Immunological needles in the gene therapy haystack: applying a genetic paradigm to gene therapy.Gene therapy · 2004Article
- Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation.Gene therapy · 2003Article
- Selectively replicating viral vectors.Cancer gene therapy · 2002Review
- Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.Journal of virology · 2002Article
- TNF-alpha -dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
- Effective repeat administration with adenovirus vectors to the muscle.Gene therapy · 2000Article
- Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity.Japanese journal of cancer research : Gann · 2000Article
- Adenoviral and adeno-associated viral transfer of genes to the peripheral nervous system.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficiency of adenovirus-mediated gene transfer is now well established. However, the cellular and the humoral immune responses triggered by vector injection lead to the rapid elimination of the transduced cells and preclude any efficient readministration. The present investigation focuses on the role of tumor necrosis factor alpha (TNF-alpha), a proinflammatory cytokine, and the related cytokine lymphotoxin alpha (LTalpha), in mounting an immune reaction against recombinant adenovirus vectors. After gene transfer in the liver, mice genetically deficient for both cytokines (TNF-alpha/LTalpha-/-), in comparison with normal mice, presented a weak acute-phase inflammatory reaction, a reduction in cellular infiltrates in the liver, and a severely impaired T-cell proliferative response to both Adenoviral and transgene product antigens. Moreover, we observed a strong reduction in the humoral response to the vector and the transgene product, with a drastic reduction of anti-adenovirus immunoglobulin A and G antibody isotypes. In addition, the reduction in antibody response observed in TNF-alpha/LTalpha-/- and TNF-alpha/LTalpha+/- mice versus TNF-alpha/LTalpha+/+ mice links antibody levels to TNF-alpha/LTalpha gene dosage. Due to the absence of neutralizing antibodies, the TNF-alpha/LTalpha knockout mice successfully express a second gene transduced by a second vector injection. The discovery of the pivotal role played by TNF-alpha in controlling the antibody response against adenovirus will allow more efficient adenovirus-based strategies for gene therapy to be proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.